| Title : Myricetin Amorphous Solid Dispersions-Antineurodegenerative Potential - Rosiak_2024_Molecules_29_ |
| Author(s) : Rosiak N , Tykarska E , Cielecka-Piontek J |
| Ref : Molecules , 29 : , 2024 |
| Abstract : Our research aimed to develop an amorphous solid dispersion (ASD) of myricetin (MYR) with Polyvinylpyrrolidone K30 (PVP30) to enhance its solubility, dissolution rate, antioxidant, and neuroprotective properties. Employing a combination of solvent evaporation and freeze drying, we successfully formed MYR ASDs. XRPD analysis confirmed complete amorphization in 1:8 and 1:9 MYR-PVP weight ratios. DSC thermograms exhibited a single glass transition (Tg), indicating full miscibility. FT-IR results and molecular modeling confirmed hydrogen bonds stabilizing MYR's amorphous state. HPLC analysis indicated the absence of degradation products, ensuring safe MYR delivery systems. Solubility, dissolution rate (pH 1.2 and 6.8), antioxidant (ABTS, DPPH, CUPRAC, and FRAP assays), and in vitro neuroprotective activities (inhibition of cholinesterases: AChE and BChE) were significantly improved compared to the pure compound. Molecular docking studies revealed that MYR had made several hydrogen, hydrophobic, and Pi-Pi stacking interactions, which could explain the compound's potency to inhibit AChE and BChE. MYR-PVP 1:9 w/w ASD has the best solubility, antioxidant, and neuroprotective activity. Stability studies confirmed the physical stability of MYR-PVP 1:9 w/w ASD immediately after dissolution and for two months under ambient conditions. Our study showed that the obtained ASDs are promising systems for the delivery of MYR with the potential for use in alleviating the symptoms of neurodegenerative diseases. |
| ESTHER : Rosiak_2024_Molecules_29_ |
| PubMedSearch : Rosiak_2024_Molecules_29_ |
| PubMedID: 38542923 |
Rosiak N, Tykarska E, Cielecka-Piontek J (2024)
Myricetin Amorphous Solid Dispersions-Antineurodegenerative Potential
Molecules
29 :
Rosiak N, Tykarska E, Cielecka-Piontek J (2024)
Molecules
29 :